Systemic therapy of onychomycosis of the feet with terbinafine: dynamics of nail rehabilitation and quality of life

Abstract

BACKGROUND: Systemic therapy with terbinafine (Exifin®) forms the basis of any treatment programs for onychomycosis of the feet of dermatomycete etiology. At the same time, the available literature presents relatively little data on the efficacy and safety of systemic terbinafine drugs for individual age groups; and there are practically no such studies based on a large statistical sample with a simultaneous assessment of the dynamics of the quality of life indicator.

AIMS: To study the use of the drug Exifin ® tablets in certain age groups of patients with mycosis and onychomycosis in clinical practice.

MATERIALS AND METHODS: The study was a multicenter observational (non-interventional) study involving 1602 patients with varying degrees of severity of onychomycosis of the feet/hands. The patients were divided into 4 age groups, each of which was divided into subgroups according to the severity of onychomycosis, from very mild to extremely severe. The positive dynamics of regression of symptoms, improvement of the quality of life according to the survey scale, the presence or absence of significant adverse reactions were evaluated.

RESULTS: In all 1602 patients, positive dynamics from the skin process was obtained in the form of regression of onychomycosis symptoms. The best results on the speed of nail sanitization were obtained in more “young” age groups with a mild degree of onychomycosis. The lowest rate of regrowth of a healthy nail plate was observed in the age groups 45–60 years and over 60 years. In the same age groups, the greatest number of persistent onychodystrophy remained after the eradication of the fungus. In all age groups, there was a positive trend in the quality of life: at the end of treatment, 67% of patients rated the quality of life as “excellent” and “good”, and another 24.1% ― “satisfactory”. No adverse events were recorded in any clinical case.

CONCLUSION: Systemic therapy with terbinafine in onychomycosis of the feet/hands is a highly effective component in the combination treatment, allowing to achieve eradication of the fungus in 85–90% of cases.

Keywords

onychomycosis / dermatophytes / terbinafine

References

[1] Sergeev AY. Fungal diseases of nails. 2nd ed. Moscow : National Academy of Mycology; 2007. 164 p. (In Russ).

[2] Сергеев А.Ю. Грибковые заболевания ногтей. 2-е изд. Москва: Национальная академия микологии, 2007. 164 с

[3] Aly R. Ecology and epidemiology of dermatophyte infections. J Am Acad Dermatol. 1994;31(3):S21–S25. doi: 10.1016/s0190-9622(08)81262-5

[4] Aly R. Ecology and epidemiology of dermatophyte infections//J Am Acad Dermatol. 1994. Vol. 31, N 3. P. S21–S25. doi: 10.1016/s0190-9622(08)81262-5

[5] Medvedeva TV. Onychomycosis. Problems of medical mycology. 2005;7(4):12–18. (In Russ).

[6] Медведева Т.В. Онихомикозы//Проблемы медицинской микологии. 2005. Т. 7, № 4. С. 12–18.

[7] Beuscher TL, Kelechi TJ. Onychomycosis: diagnosis, treatment, and prevention. J Wound Ostomy Continence Nurs. 2019;46(4):333–335. doi: 10.1097/WON.0000000000000556

[8] Beuscher T.L., Kelechi T.J. Onychomycosis: diagnosis, treatment, and prevention//J Wound Ostomy Continence Nurs. 2019. Vol. 46, N 4. P. 333–335. doi: 10.1097/WON.0000000000000556

[9] Sokolova TV, Malyarchuk AP, Malyarchuk TA. Results of a multicenter study on the study of superficial skin mycoses in the regions of the Russian Federation and the evaluation of the effectiveness of their treatment with sertaconazole. Clinical Dermatology and Venereology. 2013;11(5):28–39. (In Russ).

[10] Соколова Т.В., Малярчук А.П., Малярчук Т.А. Результаты многоцентрового исследования по изучению поверхностных микозов кожи в регионах Российской Федерации и оценке эффективности их лечения сертаконазолом//Клиническая дерматология и венерология. 2013. Т. 11, № 5. С. 28–39.

[11] Khismatullina ZR, Vlasova NA, Rustamkhanova GR. Optimization of diagnosis and treatment of patients with onychomycosis of the feet against the background of non-alcoholic fatty liver disease. Clinical dermatology and venereology. 2020;19(1):36–42. (In Russ).

[12] Хисматуллина З.Р., Власова Н.А., Рустамханова Г.Р. Оптимизация диагностики и лечения больных онихомикозом стоп на фоне неалкогольной жировой болезни печени//Клиническая дерматология и венерология. 2020. Т. 19, № 1. С. 36–42.

[13] Daggett C, Brodell RT, Daniel CR, Jackson J. Onychomycosis in Athletes. Am J Clin Dermatol. 2019;20(5):691–698. doi: 10.1007/s40257-019-00448-4

[14] Daggett C., Brodell R.T., Daniel C.R., Jackson J. Onychomycosis in Athletes//Am J Clin Dermatol. 2019. Vol. 20, N 5. P. 691–698. doi: 10.1007/s40257-019-00448-4

[15] Rukavishnikova VM. Mycoses of the feet. Moscow: EliksKom; 2003. 332 p. (In Russ).

[16] Рукавишникова В.М. Микозы стоп. Москва : ЭликсКом, 2003. 332 с.

[17] Sakania LR, Piruzyan AL, Korsunskaya IM. Modern risk factors and features of onychomycosis therapy. Medical Alphabet. 2020;(2):20–23. (In Russ). doi: 10.33667/2078-5631-2020-2-20-23

[18] Сакания Л.Р., Пирузян А.Л., Корсунская И.М. Современные факторы риска и особенности терапии онихомикоза//Медицинский алфавит. 2020. № 2. С. 20–23. doi: 10.33667/2078-5631-2020-2-20-23

[19] Solís-Arias MP, García-Romero MT. Onychomycosis in children. A review. Int J Dermatol. 2017;56(2):123–130. doi: 10.1111/ijd.13392

[20] Solís-Arias M.P., García-Romero M.T. Onychomycosis in children. A review//Int J Dermatol. 2017. Vol. 56, N 2. P. 123–130. doi: 10.1111/ijd.13392

[21] Rose AE. Therapeutic update: Onychomycosis. J Drugs Dermatol. 2014;13(10):1173–1175.

[22] Rose A.E. Therapeutic update: Onychomycosis//J Drugs Dermatol. 2014. Vol. 13, N 10. P. 1173–1175.

[23] Lateur N. Onychomycosis: beyond cosmetic distress. J Cosmet Dermatol. 2006;5(2):171–177. doi: 10.1111/j.1473-2165.2006.00246.x

[24] Lateur N. Onychomycosis: beyond cosmetic distress // J Cosmet Dermatol. 2006. Vol. 5, N 2. P. 171–177. doi: 10.1111/j.1473-2165.2006.00246.x

[25] Adaskevich VP. Diagnostic indexes in dermatology. Moscow : BINOM; 2014. 352 p. (In Russ).

[26] Адаскевич В.П. Диагностические индексы в дерматологии. Москва : БИНОМ, 2014. 352 с.

[27] Dovzhansky SI. Quality of life-an indicator of the state of patients with chronic dermatitis. Bulletin of Dermatology and Venereology. 2001;3:12–13. (In Russ).

[28] Довжанский С.И. Качество жизни ― показатель состояния больных хроническими дерматозами//Вестник дерматологии и венерологии. 2001. № 3. С. 12–13.

[29] Turner RR, Testa MA. Measuring the impact of onychomycosis on pacient quality of life. Qual Life Res. 2000;1:39–53. doi: 10.1023/A:1008986826756

[30] Turner R.R., Testa M.A. Measuring the impact of onychomycosis on pacient quality of life//Qual Life Res. 2000. N 1. P. 39–53. doi: 10.1023/A:1008986826756

[31] Federal clinical guidelines. Dermatovenerology 2015. Skin diseases. Sexually transmitted infections. Moscow: Delovoi ehkspress; 2016. Р. 275–285. (In Russ).

[32] Федеральные клинические рекомендации. Дерматовенерология 2015. Болезни кожи. Инфекции, передаваемые половым путем. Москва : Деловой экспресс, 2016. С. 275–285.

[33] Dyudyun AD, Gladyshev VV, Polion NN, Gladysheva SA. Efficiency and safety of treatment of patients with onychomycosis. Recipe. 2018;21(5):693–702. (In Russ).

[34] Дюдюн А.Д., Гладышев В.В., Полион Н.Н., Гладышева С.А. Эффективность и безопасность лечения пациентов с онихомикозом//Рецепт. 2018. Т. 21, № 5 С. 693–702.

[35] Kasymov OI, Mineeva SK, Nuraliev MD, Khamidov MF. Terbinafine in the treatment of patients with onychomycosis. Bulletin of postgraduate education in the field of healthcare. 2019;3:37–41. (In Russ).

[36] Касымов О.И., Муниева С.Х., Нуралиев М.Д., Хомидов М.Ф. Тербинафин в лечении больных онихомикозом//Вестник последипломного образования в сфере здравоохранения. 2019. № 3. С. 37–41.

[37] Roux GA, Baudraz-Rosselet F. [Algorithm to facilitate the management of onychomycosis. (In French)]. Revue Médicale Suisse. 2017;13(556):698–702.

[38] Roux G.A., Baudraz-Rosselet F. [Algorithm to facilitate the management of onychomycosis. (In French)]//Revue Médicale Suisse. 2017. Vol. 13, N 556. P. 698–702.

RIGHTS & PERMISSIONS

Eco-Vector